Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has been given an average rating of “Hold” by the twenty-three analysts that ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...